Alkermes exec sells 9,000 shares; exercises 5,000 options

Alkermes (ALKS): EVP R&D and Chief Medical Officer Craig C. Hopkinson reported insider transactions on 10/15/2025.

Rhea-AI Filing Summary

Alkermes (ALKS): EVP R&D and Chief Medical Officer Craig C. Hopkinson reported insider transactions on 10/15/2025. He exercised 5,000 options at an exercise price of $19.34 and sold 9,000 ordinary shares at a weighted average price of $31.5307 (sold in multiple trades ranging from $31.51 to $31.60). Both the option exercise and the sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025. Following these transactions, he directly beneficially owned 73,740 ordinary shares; derivative securities beneficially owned were 45,104.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Sold 9,000 shs ($284K)

Approx. gross sale proceeds $284K

Approx. exercise cost $97K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	5,000	$0.00	$0.00
Exercise	Ordinary Shares	5,000	$19.34	$97K
Sale	Ordinary Shares	9,000	$31.5307	$284K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 45,104 contracts (Direct); Ordinary Shares — 73,740 shares (Direct)

Footnotes (4)

1. F1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
2. F2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.51 to $31.60. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
4. F4. These options are fully vested in accordance with their terms.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ALKS executive Craig C. Hopkinson report?

He exercised 5,000 options at $19.34 and sold 9,000 ordinary shares at a weighted average of $31.5307 on 10/15/2025.

Were the ALKS trades under a Rule 10b5-1 plan?

Yes. Both the option exercise and the sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025.

How many ALKS shares does the insider own after the transactions?

Directly beneficially owned 73,740 ordinary shares after the reported transactions.

What were the price details for the ALKS share sale?

Weighted average price was $31.5307, with multiple trades ranging from $31.51 to $31.60.

What derivative holdings remain for the ALKS insider?

Derivative securities beneficially owned following the transactions totaled 45,104.

What is Craig C. Hopkinson’s role at Alkermes (ALKS)?

He is the company’s EVP R&D and Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/15/2025 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER ST.

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	10/15/2025		M(1)		5,000	A	$19.34	82,740	D
Ordinary Shares	10/15/2025		S(2)		9,000(3)	D	$31.5307	73,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.34	10/15/2025		M(1)			5,000	(4)	02/22/2031	Ordinary Shares	5,000	$0	45,104	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.51 to $31.60. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.